Physician profile
Daniel Elliott
NPI 1972865426
$587.10
in general payments reported to CMS, 2019-2025
15 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $35.91 · 2024: $193 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $124.72 | 2022 | |
| Novo Nordisk INC | $81.85 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $74.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $42.55 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $42.42 | 2024 | Trelegy Ellipta |
| Abbott Laboratories | $36.73 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $30.22 | 2023-2025 | Mounjaro, Zepbound |
| Alkermes, INC. | $24.35 | 2024 | Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.32 | 2024 | Xifaxan |
| Pfizer INC. | $19.95 | 2025 | |
| Corcept Therapeutics | $18.89 | 2025 | Korlym |
| Dynavax Technologies Corporation | $18.19 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $17.05 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Abbvie INC. | $15.98 | 2024 | |
| Currax Pharmaceuticals LLC | $15.79 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.